SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of April, 2015
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address
of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits
the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private
issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82 -
|
EXHIBIT
NUMBER |
|
DESCRIPTION |
| |
|
|
| 99.1 |
|
News
Release Dated April 28, 2015 - Oncolytics Biotech® Inc. Announces Extension to Regain Compliance with Nasdaq's Minimum Bid Price Rule |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Oncolytics Biotech Inc.
(Registrant) |
| |
|
|
| |
|
|
| Date:
April 28, 2015 |
By: |
/s/ Kirk Look |
| |
|
Kirk Look |
| |
|
Chief Financial Officer |
Exhibit 99.1
Oncolytics Biotech® Inc. Announces Extension to Regain Compliance
with Nasdaq's Minimum Bid Price Rule
CALGARY, April 28, 2015 /CNW/ - Oncolytics Biotech®
Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it has received a letter from
the NASDAQ OMX Group ("Nasdaq") determining that the Company is eligible for an additional 180-calendar day period, until
October 26, 2015, to regain compliance with the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2).
Per the notice of deficiency received
on October 29, 2014, Oncolytics had a period of 180-calendar days, or until April 27, 2015, to regain compliance with the minimum
bid price requirement. Following a review, Nasdaq determined that the Company was eligible to receive an additional 180-day period
on the basis that Oncolytics still met the continued listing requirement for market value of publicly held shares and all other
initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and had provided
written notice of its intention to cure the minimum bid price deficiency during the second 180-day compliance period by effecting
a reverse stock split, if necessary.
The Company's shares continue to trade
on the Toronto Stock Exchange ("TSX") under the symbol "ONC" and are in full compliance with TSX listing requirements.
The Company's listing on the TSX is completely independent of, and will not be affected by, the status of its Nasdaq listing.
If compliance cannot be demonstrated
by October 26, 2015, Nasdaq staff will provide written notification that the Company's securities will be delisted. At that time,
the Company may appeal Nasdaq staff's determination to a Hearings Panel.
About Oncolytics Biotech®
Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking
statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended,
and forward-looking information within the meaning of Canadian securities laws. Statements, other than statements of historical
facts, included in this press release that address activities, events or developments that Oncolytics expects or anticipates will
or may occur in the future, including such things as the actions that could be taken by members of the Nasdaq staff, and any exercise
of discretion by members of the Nasdaq staff with respect to compliance by the Company with the Nasdaq Listing Rules, and other
such matters are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties,
which could cause the Company's actual results to differ materially from those in the forward-looking statements and forward-looking
information. Such risks and uncertainties include, among others, risks related to market conditions. Investors should consult the
Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statement and forward-looking information. Investors are cautioned against placing
undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update these forward-looking
statements and forward-looking information, except as required by applicable laws
SOURCE Oncolytics Biotech Inc.
%CIK: 0001129928
For further information: TMX Equicom: Nick Hurst, 300 5th
Ave. SW, 10th Floor, Calgary, Alberta T2P 3C4, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@tmxequicom.com; TMX Equicom: Michael
Moore, San Diego, CA, Tel: 858.886.7813, mmoore@tmxequicom.com; Dian Griesel, Inc.: Susan Forman, 335 West 38th Street, 3rd Floor,
New York, NY 10018, Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 18:22e 28-APR-15